Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great post JDT188. It is pretty evident to me that the company is positioning itself very well to move forward nicely. Holding for results which will come when they are complete. No scientists here so I will defer to Dr Von Hoff and TD2s professional handling and delivery...
Last half hour of trading was very interesting. Looked like a battle....
Pharmacyte Biotech Makes Good Cancer Drugs Even Better (CELG, LLY, PMCB, RHHBY)
Celgene Corporation (NASDAQ:CELG), Roche Holding Ltd. (OTCMKTS:RHHBY) and Eli Lilly and Co. (NYSE:LLY) all have the right idea, but it's Pharmacyte Biotech Inc. (OTCMKTS:PMCB) that may well perfect the premise.
By James E. Brumley
May 5, 2015 7:58:14 AM PDT | 91
While hearing the words "you've got cancer" is devastating, perhaps the most terrifying derivative of that message is "you've got pancreatic cancer." It's arguably the least treatable of all forms of cancer, with the average patient - with the best-known treatment - only living an average of 8.5 months one diagnosed. Less than 7% of all pancreatic cancer sufferers live more than five years. A small biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), however, may soon be improving those survival numbers.
It's not from a lack of trying there are so few FDA-approved treatments for pancreatic cancer. Over 30 trials targeting the disease have been performed over the past fifteen years, and only two have won the administration's blessing and been allowed to be marketed as a therapy. One of those treatment options is the combination of gemcitabine, made by Eli Lilly and Co. (NYSE:LLY), with Tarceva, made by Roche Holding Ltd. (OTCMKTS:RHHBY). The other is gemcitabine used in conjunction with Abraxane, from Celgene Corporation (NASDAQ:CELG). The combination of Abraxane with gemcitabine is the "go to" option in most cases, as it's shown the best efficacy.
Though the drug molecules involved are complex, the science of the treatment is simple enough. Gemcitabine kills cancer cells by disrupting the reproduction of cancer cells (by attaching to a cancer cell's DNA), leading to the death of that cell before it can reproduce again. Simultaneously, not only does Abraxane kill cancer cells (by opening up more pathways for chemotherapy paclitaxel to enter cancer cells), but it also produces molecules that prevent the cytidine deaminase (or CDA) from forming. CDA can break gemcitabine down before it has a chance to do its work.
Pharmacyte Biotech is taking an R&D route that isn't designed to improve the efficacy of gemcitabine. Rather, Pharmacyte's researchers they can improve on the efficacy of a drug called ifosfamide.
Ifosfamide, like gemcitabine, inhibits the creation of proteins and recreation of DNA that would normally occur when a cancerous cell is dividing, thus blocking the replication of cancerous cells. Pharmacyte Biotech, however, has built the proverbial better mousetrap by improving the way ifosfamide is delivered to a patient.
The technology is called Cell-in-a-Box. In simplest terms, it's a means of placing thousands of live cells inside a capsule that's about the size of the head of a pin. The cells inside the capsule produce a P450 enzyme, which can activate an otherwise inactive form of ifosfamide to produce an anti-cancerous effect.
The upside to this approach is pin-point placement.
Ifosfamide in its active form is usually delivered intravenously and then activated in the liver. The process "works", but much of the drug doesn't make it to the pancreas. To deliver a dose big enough to make a dent in a pancreatic tumor, nasty side effects are almost a given. The Cell-in-a-Box approach circumvents this inefficient form of delivery by inserting encapsulated P450-producing cells very near the tumor itself, which means ifosfamide isn't activated until it's at or near the pancreatic tumor, which means the bulk of the drug is delivered where it needs to be delivered, which in turn means less of the drug is necessary to produce a response. Less of a drug means fewer side effects.
And yes, Pharmacyte Biotech has demonstrated measurable efficacy with this approach.
In a phase 1/2 trial examining the benefit of the Cell-in-a-Box delivery of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients.
There's still work to be done. The company reports it's aiming to begin phase 2b trials of Cell-in-a-Box in conjunction with ifosfamide in Australia in the third quarter of this year, which will compare it to the current preferred treatment... the combination of Abraxana and gemcitabine. The results achieved this far, though, look promising. Meanwhile, Pharmacyte Biotech is planning a phase 1 trial of the biotechnology in the United States that will specifically target the development of ascites fluid in the abdomen pancreatic cancer patients. Aside from being uncomfortable, this ascites fluid can also spur the spread of cancer outside of the pancreas.
Bottom line? Few may have noticed, but the Cell-in-a-Box biotechnology from Pharmacyte has the potential to be a game-changer in an arena where there are few options. At stake is a $1 billion pancreatic cancer market that, to put it plainly, is still waiting for a truly great therapy. In the meantime (as veteran biotech traders can attest) a finished and approved drug isn't necessary to push a stock higher. Progress and strong preliminary results are often more than enough to fan the bullish flames. Pharmacyte seems to have plenty of both on tap.
Not sure why the count down but we are awaiting the results for our extended preclinical study. The initiall study started in August 2014 and we got preliminary results in October. Since it took 3 months last year, we are thinking we should hear something this month. Here is some info on the studies with TD2.
http://www.pharmacytebiotech.com/pharmacyte-biotech-provides-update-on-corporate-developments-and-progress-with-cancer-and-diabetes-programs/
Thanks bio. I just like managing by facts.
I wasn't answering the question for the poster. I just wanted to provide information for anyone else who would have liked some DD to decide for themselves.
Well, it is a name of notoriety, especially in the pancreatic cancer arena. And for this little penny stock to have him come to us, is pretty amazing...
We are just excited to have him on board and please don't be a stranger when we do get word from him. I would love to revisit this conversation at that time...
Not name dropping at all. This is straight from the most recent 10q...
"The strategy of the Company to achieve its goals includes several primary components:
The conducting of preclinical studies and clinical trials that will examine the effectiveness of the Company’s pancreatic cancer treatment in ameliorating the pain and accumulation of malignant ascites fluid in the abdomen that are characteristic of pancreatic cancer. These studies and trials will be conducted by Translational Drug Development in the United States"
Straight from the TD2 web page...
"Daniel D. Von Hoff, M.D., F.A.C.P. is currently Chief Development Officer at TD2. He also serves as Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona, as well as Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ."
And...
"The study will be conducted by Translational Drug Development (TD2) in the U.S. which was designed by pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2."
http://www.pharmacytebiotech.com/pharmacyte-biotech-initiates-expanded-follow-study-united-states-accumulation-malignant-ascites-fluid/
http://client.irwebkit.com/PharmaCyteBiotech/form/10-q
http://www.td2inc.com/leadership/daniel-von-hoff
Here is one place he will be...
http://www.seenamagowitzfoundation.org/wp-content/uploads/2015/03/SMF_2015_Invite_.pdf
And here is a video from the same event a couple of years back...
Good to hear from you Bill. What a nice way to retire. Yes, we are maintaining well and hoping to hear study results soon.
Liquard purchasing the 250,000 shares at .159 is $39,750. That is money coming out of his own pocket! And, he will make less than that in a year's salary at PMCB, 9,000 x 4 = $36,000,
I would say reading between the lines is very important to do here. I would further venture to say that our current board is confident about the future value of this stock in making such an offer.
http://biz.yahoo.com/e/150429/pmcb8-k.html
Closed just above the 20dma on very low volume... :)
So much on the horizon...
I will be here when it all comes to fruition...
http://www.pharmacytebiotech.com/pharmacyte-biotech-on-track-to-commence-clinical-trials/
http://www.pharmacytebiotech.com/new-research-shows-pharmacyte-biotechs-melligen-cell-line-can-reverse-diabetes/
I agree with you. That was exactly my take on him. He would not align himself wit a loser. His pay from the company will come primarily as a result of his personal purchase of 250k shares @.159 since he is only receieving 9k a quarter in cash. It is my opinion that he and the other directors believe this share purchase in the end will pay him very handsomely...
He will be making a personal investment in the company with this 250k purchase...
That speaks volumes, IMO...
Fabulous post, techi!
Did you read the article I posted?
"The one-year survival rate in the first trial was 36%, which is twice that of gemcitabine (Table 5). "
We beat the Gold Standard by twice the one-year survival rate.
And the current studies are for pain and malignant ascites for which there are no studies. This is a study designed by Dr Von Hoff and his TD2 team.
"Because there are no suitable preclinical models for studying this pancreatic cancer-associated pain, the “pain-reducing” aspect of PharmaCyte Biotech’s pancreatic cancer treatment will be studied in an early-phase clinical trial conducted in the U.S. by TD2. This clinical trial is expected to begin late in the third quarter of 2015."
http://www.pharmacytebiotech.com/pancreatic-cancer/
PMCB is a biotech. Trials and studies take time. The longs you are referring to are just biding our time and waiting. The technology has been proven in the past and will be proven again, IMO. I can wait...
http://www.mdpi.com/1999-4923/6/3/447
This collaborative infrastructure looks to be a very solid and effective foundation on which to build our diabetes trials.
"Typically, preclinical research and animal studies are performed and executed one at a time. The Consortium’s multiple studies are being simultaneously implemented with slightly different designs and objectives in order to accelerate the R&D process. This streamlining should substantially reduce the time to human clinical trials."
"To swiftly reach this objective, Consortium members are leveraging their individual strengths and animal studies capabilities, by using their unique models to work concurrently and in tandem. As a result, the Consortium’s diabetes research studies may be some of the comprehensive concurrent efforts undertaken in years."
Human trials are certainly a couple of years away but the chances for success are greatly enhanced by this consortium, IMO.
http://www.goldmanresearch.com/20150428977/Opportunity-Research/unprecedented-diabetes-research-collaboration-to-lead-to-expedited-pharmacyte-biotech-clinical-trials.html
Always enjoy a good chart reading. Thanks....
Always such good DD Rudy... Thanks
Pharmacyte Biotech Finalizes International Diabetes Consortium to Cure Diabetes
SILVER SPRING, Md., April 20, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced that the world class team of scientists, physicians and academics that make up its international Diabetes Consortium is now complete with the addition of the final two members, Dr. Thomas Stratmann and Dr. Axel Kornerup Hansen.
Dr. Stratmann is an Associate Professor at the Department of Physiology and Immunology in the Faculty of Biology at the University of Barcelona in Spain. Dr. Stratmann has extensive experience in using a diabetes mouse model of Type 1 diabetes in which the disease develops rapidly in contrast to other mouse models where the disease only develops after several weeks. Through the use of this model as the Consortium progresses in its animal preclinical studies with Cell-in-a-Box(R)-encapsulated Melligen cells, it is fully expected that the overall development timeline for PharmaCyte Biotech's diabetes treatment will be shortened significantly.
Dr. Kornerup Hansen is a Professor in the Department of Veterinary Disease Biology at the University of Copenhagen in Denmark. He will perform specially designed preclinical studies to determine the minimum dose of encapsulated Melligen cells that will normalize blood glucose levels in diabetic rats as well as pigs, which are an important model for mimicking the dosing that will be required for human patients.
PharmaCyte Biotech has the exclusive worldwide rights to use the Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. When Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.
PharmaCyte Biotech's CEO, Kenneth L. Waggoner, said of the 16-member Diabetes Consortium, "We are very pleased that our international Diabetes Consortium is now complete after only a few months of development. We feel that the scientists, physicians and academics that make up our Consortium are of the highest caliber and have already proven that they can work in concert as the development of our diabetes treatment progresses. We firmly believe that, although the members within the Consortium are diverse in terms of their geographic location and expertise, their talents and knowledge are most complementary. Because of this, PharmaCyte Biotech's treatment for insulin-dependent diabetes could be in clinical testing much sooner than would otherwise be the case."
PharmaCyte Biotech's Diabetes Consortium brings together a global coalition of world class experts from various universities and institutions in several countries around the world. All members of the Consortium are committed to developing a treatment for insulin-dependent diabetes using PharmaCyte Biotech's Cell-in-a-Box(R) cellulose-based live-cell encapsulation technology combined with human non-pancreatic, insulin-producing cells (Melligen Cells).
Members of the Diabetes Consortium have all agreed to bring their expertise to the Consortium and work in concert to develop a treatment for diabetes. In view of the considerable collective experience and through their collaborative efforts, the timeline for the development of PharmaCyte Biotech's diabetes treatment will be significantly shortened. The members of the Consortium and their expected contributions are:
Dr. Eva-Maria Brandtner, Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and TreatmentProgram Development for the Consortium. Dr. Brandtner will coordinate all of the Diabetes Consortium's research activities and also have a scientific advisory role. Dr. Brandtner previously served as Chief Scientist at Austrianova where she conducted studies related to the encapsulation of Melligen Cells and the early testing of their use in PharmaCyte Biotech's encapsulation technology as a treatment for diabetes. Dr. Brandtner serves as PharmaCyte Biotech's Director of Diabetes Program Development and is a consultant to PharmaCyte Biotech.
Dr. Matthias Lohr, Professor of Gastroenterology and Hepatology at the Karolinska Institute in Stockholm, Sweden, will serve a pivotal scientific advisory role for the Diabetes Consortium. Dr. Lohr is exceedingly familiar with the Cell-in-a-Box(R) technology having served as Principal Investigator for the clinical trials in pancreatic cancer that employed the technology together with the cancer chemotherapy drug ifosfamide. In addition to pancreatic cancer, Dr. Lohr has a specialty in diabetes and its treatment and believes that the Cell-in-a-Box(R) technology will provide a platform upon which effective treatments for both pancreatic cancer and diabetes can be built. Dr. Lohr is a consultant to PharmaCyte Biotech and the Chairman of PharmaCyte Biotech's Scientific Advisory Board.
Prof. Walter H. Gunzburg, Dr. Brian Salmons and Dr. John Dangerfield of Austrianova will all play significant scientific advisory roles. Prof. Gunzburg is Chief Technical Officer of Austrianova and serves as PharmaCyte Biotech's Chief Scientific Officer. He is also Professor of Virology at the University of Veterinary Medicine in Vienna (VetMed). Dr. Salmons is the CEO and President of Austrianova and is a member of the Scientific Advisory Board of PharmaCyte Biotech. Prof. Gunzburg and Dr. Salmons co-developed the Cell-in-a-Box(R) technology and thus are the world's experts in its potential use for the treatment of diseases. Both are also consultants to PharmaCyte Biotech. Dr. Dangerfield, the COO of Austrianova, is intimately involved in dealing with the Cell-in-a-Box(R) encapsulation process on a daily basis. All three will be responsible for the preparation of cells and their encapsulation as required for preclinical studies and ultimately be involved in human clinical trials as the Diabetes Consortium develops its diabetes treatment.
Prof. Ann Simpson and Dr. Brenton Hamdorf of the University of Technology in Sydney (UTS), Australia, and their scientific colleagues at UTS are essential to the success of the efforts of the Diabetes Consortium. Dr. Simpson, Professor of Biochemistry at UTS, has spent a significant portion of her professional career in developing and characterizing the non-pancreatic insulin-producing Melligen Cells that will be encapsulated using the Cell-in-a-Box(R) technology to produce PharmaCyte Biotech's treatment for insulin-dependent diabetes. Prof. Simpson serves as a consultant to PharmaCyte Biotech. Dr. Hamdorf serves as UTS' business development contact and partner for the Diabetes Consortium. Dr. Simpson and her fellow scientists at UTS will be responsible for performing laboratory and animal studies on the Melligen Cells both before and after encapsulation that will be necessary for defining the parameters under which the Melligen Cells produce insulin.
Dr. Constantine Konstantoulas and Mag Helga Petznek (veterinarian) of VetMed will be responsible for conducting animal studies with encapsulated Melligen Cells that will test the potential of these cells to produce tumors, define the biocompatibility of the encapsulated Melligen Cells and test the ability of the encapsulated cells to produce insulin in a mouse model in which Type 1 diabetes has been induced by the introduction of a virus. Dr. Konstantoulas will coordinate the day-to-day activities of these tests, and Prof. Walter H. Gunzburg will oversee all of the studies done at VetMed. The studies at this institution are already underway.
Dr. Thomas Stratmann, Associate Professor at the Department of Physiology and Immunology in the Faculty of Biology at the University of Barcelona in Spain, has extensive experience in using a diabetes mouse model of Type 1 diabetes in which the disease develops rapidly. Through the use of this model, as the Diabetes Consortium progresses in its animal preclinical studies with Cell-in-a-Box(R)-encapsulated Melligen Cells, it is fully expected that the overall development timeline for PharmaCyte Biotech's diabetes treatment will be considerably shortened. In addition, Dr. Stratmann has two other mouse models of Type 1 diabetes in his laboratory. Through the use of these other animal models, and in combination with other test systems, the Consortium should be able to obtain irrefutable data as to the effectiveness of PharmaCyte Biotech's diabetes treatment.
Prof. Axel Kornerup Hansen, Professor in the Department of Veterinary Disease Biology at the University of Copenhagen in Denmark, will perform preclinical studies to determine the minimum dose of encapsulated Melligen Cells that will normalize blood glucose levels in diabetic rats. In addition, Dr. Hansen will perform the same tests on pigs that have been made diabetic by injecting them with a drug known as streptozotocin. This drug destroys the ability of the pancreas to produce insulin and thus results in diabetes.
Dr. Andreas Blutke, Dr. Rudiger Wanke, and Dr. Eckhard Wolf, of the Laboratory of Functional Genome Analysis, Gene Center, at the Ludwig-Maximillians University in Munich, Germany, have developed unique transgenic mouse and pig models in which the mice and pigs exhibit diabetes from birth without the use of diabetes-inducing drugs. When these models are ready, they will be used by the Diabetes Consortium to test the effectives of PharmaCyte Biotech's diabetes treatment and to study the effectiveness of the treatment in minimizing the kidney and pancreas alterations that occur as diabetes progresses.
Kenneth L. Waggoner, JD and Dr. Gerald W. Crabtree, the CEO and the COO, respectively, of PharmaCyte Biotech will be responsible for providing overall coordination and management of the Diabetes Consortium as well as and funding for the activities within the Consortium. PharmaCyte Biotech will also provide scientific direction and support when it is required.
http://finance.yahoo.com/news/pharmacyte-biotech-finalizes-international-diabetes-133000092.html
I don't think so, no...
JMO, but I think we are finally becoming well-known. Word of mouth is powerful and it looks like the word may even be getting to big money. Now, does so that mean they know something we don't? Or do they now just know what we longs know? IDK...
But I do know that there has been a ton of buying, and where sell off use to take us down, the buying has been major support. For that reason, I think this must be big $. So if big money now has us on their radar, we will know eventually as it will need to be reported, quarterly.
We know we are becoming more well-known simply by the fact that we see our story being told in other than PRs now.
If you know about Cell in a Box technology, it would not surprise that folks would be interested in investing here. The potential upside is exponential. We are developing treatments for which there is currently none and Dr Von Hoff is helping us on one of those journeys.
http://coloncancernewstoday.com/2015/04/13/pancreatic-cancer-drug-works-against-accumulation-of-malignant-ascites-fluid-in-colon-cancer-patients/
And I think just the opposite of you, LuCo. I don't think it was very smart to pull out today, or any day for that matter. Volume is not up up this much for no reason and buys still out numbered sells.
Besides, Cell in a Box technology is the investment here and it is noteworthy, for sure. Von Hoff will be confirming that in the near future.
That's a fact and many are now invested here...
Not this kind of volume consistently over days...
16M traded in first 3 hours and buys just out number sells. The interest in this technology has not waned and the stock and company are being strengthened by true investors, IMO.
Yeah, good for her! Nice post trently.
I agree. Selling now may mean paying a higher premium in the future. The gaining interest in this technology may continue to drive up the price here...
10.5m in one hour! And selling is almost matching buying. And we continue to rise!
This heavy volume started the day after Liquard's appointment announcement. I am wondering if that has gotten some folks attention especially in light of his experiences.
That's crazy. I wish I could have heard that interview.
LMAO! That is fabulous! I think you held a good one... :)
Good point. There is rarely just one factor at play. It's like the perfect storm right now, all factors merging! We are getting ready for something very big...
That is a really good question. I was thinking that more folks are aware and now buying in with big news on the horizon. I am pretty certain Goldman Research reaches a lot of retail investors and he has been reporting quite a bit lately on the company. I still see short play involved 43% shorted yesterday but the buying has been dominating.
5.5 M traded in first 2 hours... Second day in a row we may hit over 9 million. Amazing,..
Yes, a piece of that $176 B market would be nice. With this technology, we just may dominate the market as well...
That is the key Rob. No one should be short sited here. This is a definite big future play IMO. TD2 will be sharing results in the near term and when that happens... I wouldn't want to have MY money anywhere else...
It has been lasting for weeks now. Volume continues to rise. The word is out. Folks can buy this revolutionary technology at under .20 a share right now. I don't think there will be much selling before we hear from Dr Von Hoff. And when we do hear from him, I think the buying will continue to dominate the selling.
As you know, I have always been a strong believer in this technology but figured no one really knew about it yet. Well Trader, I think the word is out and many want in... Look at all that buying pressure!